-
Rodman & Renshaw Sees 160% Upside For NeuroMetrix
Tuesday, June 28, 2016 - 12:04pm | 359Read More...Rodman & Renshaw started coverage of Neurometrix Inc (NASDAQ: NURO) with a Buy rating and a target price of $4.50, implying an upside of 160 percent. NeuroMetrix is medical device company aimed at management of chronic intractable pain due to conditions such as diabetes, fibromyalgia and...
-
Winners And Losers (So Far) From CES 2016
Wednesday, January 6, 2016 - 3:24pm | 348Read More...Several companies have emerged as big winners during the 2016 Consumer Electronics Show, while investors punished others. Winners Shares of Netflix, Inc. (NASDAQ: NFLX) surged higher by more than 6 percent on Wednesday after the company's CEO, Reed Hastings, took center stage at CES and...
-
NeuroMetrix Announces FDA Clearance For Upgraded Version Of Quell, Shares Surge
Wednesday, January 6, 2016 - 2:22pm | 199Read More...Shares of Neurometrix Inc (NASDAQ: NURO), a healthcare company that develops wearable medical technology, announced during CES 2016 it received clearance from the U.S. Food and Drug Administration for an upgraded version of Quell, a chronic pain relief wearable. Neurometrix also confirmed the...
